Last reviewed · How we verify
Pembrolizumab plus chemotherapy
Approved treatments
- Avelumab (MSB0010718C) · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pembrolizumab plus chemotherapy patent landscape — cliff calendar, originator estates, attackable patents
- Pembrolizumab plus chemotherapy treatment landscape brief
- Pembrolizumab plus chemotherapy treatment updates RSS
Frequently asked questions about Pembrolizumab plus chemotherapy
What drugs treat Pembrolizumab plus chemotherapy?
Tracked treatments include Avelumab (MSB0010718C).
What is the treatment for Pembrolizumab plus chemotherapy?
Standard treatment for Pembrolizumab plus chemotherapy includes Avelumab (MSB0010718C). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pembrolizumab plus chemotherapy patent cliff · Pembrolizumab plus chemotherapy CI report
- Treatment: Avelumab (MSB0010718C) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing